Search

Harikrishna Nakshatri

from Zionsville, IN
Age ~64
Get Report
Also known as:
Harikrish Nakshatri, Harik Nakshatri, Nakshatri Harikrishna
Related to:
Sapna Nakshatri, 22Swetha Nakshatri, 26Poornima Nakshatri, 56
Connected to:
Kayla C Naktewa, 40Sanije Nakuci, 58Bharat C Nakum, 56Karen Nakushian, 64Adam K Nakutis, 37Kathleen A Nakutis, 66Syed R Nakvi, 61Darius Nakvosas, 51Kenneth M Nalaboff, 54Chandra S Nalamalapu, 70

Harikrishna Nakshatri Phones & Addresses

  • Zionsville, IN
  • 3127 Woodlane Ct, Indianapolis, IN 46268 (317) 388-9582
  • Port Washington, NY
  • Marion, IN
  • 3127 Woodlane Ct, Indianapolis, IN 46268 (317) 502-9009

Work

Company: Indiana university Position: Professor at indiana university

Education

Degree: Bachelor's degree or higher

Emails

h***[email protected]

Industries

Research

Resumes

Resumes

Harikrishna Nakshatri Photo 1

Professor At Indiana University

View page
Location:
425 east Kirkwood Ave, Bloomington, IN 47408
Industry:
Research
Work:
Indiana University
Professor at Indiana University

Publications

Us Patents

Use Of Parthenolide To Inhibit Cancer

View page
US Patent:
20030125373, Jul 3, 2003
Filed:
Jun 21, 2002
Appl. No.:
10/178054
Inventors:
Harikrishna Nakshatri - Indianapolis IN, US
Christopher Sweeney - Indianapolis IN, US
International Classification:
A61K031/365
A61K031/337
US Classification:
514/449000, 514/468000
Abstract:
The invention provides a method comprising the use of parthenolide, including its analogs, to treat cancer or conditions characterized by abnormal angiogenesis.

Use Of Parthenolide To Inhibit Cancer

View page
US Patent:
20050143451, Jun 30, 2005
Filed:
Feb 22, 2005
Appl. No.:
11/063144
Inventors:
Harikrishna Nakshatri - Indianapolis IN, US
Christopher Sweeney - Indianapolis IN, US
International Classification:
A61K031/365
US Classification:
514468000
Abstract:
The invention provides a method comprising the use of parthenolide, including its analogs, to treat cancer or conditions characterized by abnormal angiogenesis.

Cancer Therapy Prognosis

View page
US Patent:
20100068717, Mar 18, 2010
Filed:
Jan 30, 2008
Appl. No.:
12/524845
Inventors:
Sunil Badve - Indianapolis IN, US
Harikrishna Nakshatri - Zionsville IN, US
Assignee:
INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION - Indianaplois IN
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Methods and compositions based on FOXA1 expression to predict long-term disease-free survival in patients with breast cancer are disclosed. In ER+ positive patients, expression of FOXA1 is useful in identifying a subgroup of patients with a better prognosis. FOXA1 expression correlates with luminal subtype breast cancer, and serves as a clinical marker for luminal subtype breast cancer. Expression of FOXA1 is useful as a prognostic marker for an effective response tumors and as a predictive marker for a greater likelihood of response to an anti-hormonal therapy. Prognostic ability of FOXA1 in low-risk breast cancers is useful in treatment decision making.

Diagnostic Methods And Kit For Detecting Cancer

View page
US Patent:
20120252907, Oct 4, 2012
Filed:
Mar 29, 2012
Appl. No.:
13/433722
Inventors:
Harikrishna NAKSHATRI - Zionsville IN, US
Assignee:
Indiana University Research and Technology Corporation - Indianapolis IN
International Classification:
C12Q 1/68
A61P 35/00
A61K 35/00
US Classification:
514789, 435 612, 435 611
Abstract:
The present disclosure is directed to compositions and methods for detecting elevated microRNA U6 concentrations in serum relative to a standard microRNA (e.g. SNORD44) as a diagnostic indicator of metastatic disease. In one embodiment the methods of the present disclosure are used to diagnose the existence of, or assess the risk of, breast cancer in an individual.

Materials And Methods For Diagnosing And Predicting The Course Of Prostate Cancer

View page
US Patent:
20130202717, Aug 8, 2013
Filed:
Jun 1, 2011
Appl. No.:
13/700777
Inventors:
Sunil Badve - Indianapolis IN, US
Harikrishna Nakshatri - Indianapolis IN, US
Assignee:
INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION - Indianapolis IN
International Classification:
G01N 33/68
US Classification:
424649, 435 71, 435 32, 435 612, 435 611
Abstract:
Expression of Forkhead-box protein A1 (FOXA1), a transcription factor important for the normal development of the prostate gland is thought to be controlled by steroid hormones and GATA-3. Expression of FOXA1, GATA-3 and androgen receptor (AR) was retrospectively analyzed by immunohistochemistry (IHC) in a series of 80 primary tumors and 28 metastatic prostate cancers including 15 matched paired samples. High nuclear FOXA1 expression was seen in 19% of primary tumors and 89% of metastatic tumors (p

Materials And Methods For Diagnosing And Predicting The Course Of Prostate Cancer

View page
US Patent:
20170030916, Feb 2, 2017
Filed:
Sep 21, 2016
Appl. No.:
15/271988
Inventors:
- Indianapolis IN, US
Harikrishna Nakshatri - Indianapolis IN, US
International Classification:
G01N 33/574
C12Q 1/68
Abstract:
Expression of Forkhead-box protein A1 (FOXA1), a transcription factor important for the normal development of the prostate gland is thought to be controlled by steroid hormones and GATA-3. Expression of FOXA1, GATA-3 and androgen receptor (AR) was retrospectively analyzed by immunohistochemistry (IHC) in a series of 80 primary tumors and 28 metastatic prostate cancers including 15 matched paired samples. High nuclear FOXA1 expression was seen in 19% of primary tumors and 89% of metastatic tumors (p
Control profile
Harikrishna Nakshatri from Zionsville, IN, age ~64 Get Report